Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03424018 · ClinicalTrials.gov registry record · Phase 3
An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia
A Phase 3 study of Achondroplasia, sponsored by BioMarin Pharmaceutical.
- Active
- Registry status
- Phase 3
- Development phase
- 119
- Enrollment target
- 20
- Study locations
NCT03424018: Active Phase 3 study of Achondroplasia, sponsored by BioMarin Pharmaceutical.
NCT03424018 is a Phase 3 study of Achondroplasia that is active but no longer recruiting, run by BioMarin Pharmaceutical. The registered enrollment target is 119 participants, below the 138-participant average among 9 other Achondroplasia trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03424018, a Phase 3 study of Achondroplasia, is active but no longer recruiting, sponsored by BioMarin Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 119 participants
- Enrollment target
- 20
- Study locations
Study Summary
The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
Primary Outcome
Long term efficacy as measured by change in annualized growth velocity
Conditions Studied
Interventions
- DRUG BMN 111
Study Locations (20)
Other
- Otto-von-Gericke Universitaet, Universitaetskinderklinik - Magdeburg
- Universitätsklinikum Münster - Münster
- Osaka University Hospital - Osaka
- Saitama Children's Medical Center - Saitama
- Tokushima University Hospital - Tokushima
- Institut Catala de Traumatologica I Medicina de l'Esport - Barcelona
- Hospital Sant Joan de Deu - Barcelona
California
- Children's Hospital & Research Center Oakland - Oakland
- Harbor - UCLA Medical Center - Torrance
Delaware
- Alfred I. duPont Hospital for Children - Wilmington
Georgia
- Emory University - Atlanta
Illinois
- Ann and Robert H. Lurie Children's Hospital of Chicago - Chicago
Maryland
- Johns Hopkins University - Baltimore
Missouri
- University of Missouri - Columbia
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2017-12-12 |
| Est. Completion | 2031-06 |
| Phase | Phase 3 |
What the registry record for NCT03424018 still lists
NCT03424018 is an interventional study that assigns participants to a tested intervention. The registered 119 participants enrollment target is mid-sized for trials with a published cap, below the 138-participant average among 9 other Achondroplasia trials with a reported enrollment target (14% lower).
The record links to 1 condition, with Achondroplasia appearing as the primary indexed condition, and to 1 intervention - of which BMN 111 is the first listed.
NCT03424018 names 20 study sites across 13 states, led by Other, California, Delaware.
Frequently Asked Questions
What is clinical trial NCT03424018 about?
NCT03424018 is a clinical study titled "An Extension Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia". The intent and design of this Phase 3 study is to assess BMN 111 as a therapeutic option for the treatment of children with Achondroplasia
What is the current status of trial NCT03424018?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 119 participants. The study started on 2017-12-12. Estimated completion is 2031-06.
What conditions does trial NCT03424018 study?
This clinical trial studies the following conditions: Achondroplasia.
What interventions are being tested in trial NCT03424018?
The interventions under investigation include: BMN 111 (DRUG).
Who is sponsoring clinical trial NCT03424018?
This trial is sponsored by BioMarin Pharmaceutical, which has 80 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03424018 being conducted?
This trial has 20 study locations across California, Delaware, Georgia, Illinois, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03424018's enrollment target sits among peer trials
119 4th of 9 higher than 6 of 9 other Achondroplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Achondroplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
RECRUITING · Phase 2
-
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
RECRUITING · Phase 2
-
VIrtual STudy in Achondroplasia for the US (VISTA)
RECRUITING
-
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04870762 · 119 participants · Phase 2
Customized 3D Printed Oral Stents During Head and Neck Radiotherapy
- NCT05559853 · 119 participants
Developing a New MRI Technique to Understand Changes in Brain Tumors After Treatment
- NCT06564389 · 119 participants · Phase 1
FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients
- NCT06742801 · 119 participants · NA
Onyx™ Liquid Embolic IDE Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI